| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
93.33(B) |
| Last
Volume: |
13,665,305 |
Avg
Vol: |
12,012,333 |
| 52
Week Range: |
$40.25 - $66.16 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$0 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
18,718 |
616,397 |
| Total Sell Value |
$0 |
$0 |
$1,146,397 |
$44,859,834 |
| Total People Sold |
0 |
0 |
2 |
5 |
| Total Sell Transactions |
0 |
0 |
2 |
11 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Santiago Karen Murphy |
Controller |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,825 |
6,850 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(335) |
4,927 |
|
- |
|
| Schmukler Louis S |
Pres., Global Mfg. & Supply |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$535,278 |
D/D |
(10,416) |
56,963 |
|
- |
|
| Schmukler Louis S |
Pres., Global Mfg. & Supply |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,568 |
63,652 |
|
- |
|
| Schmukler Louis S |
Pres., Global Mfg. & Supply |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,020) |
48,839 |
|
- |
|
| Elicker John E |
SVP, Public Affairs & IR |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$233,311 |
D/D |
(4,540) |
89,471 |
|
- |
|
| Elicker John E |
SVP, Public Affairs & IR |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,180 |
92,626 |
|
- |
|
| Elicker John E |
SVP, Public Affairs & IR |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,137) |
84,974 |
|
- |
|
| Biondi Paul |
SVP, Head of Strategy & BD |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$163,831 |
D/D |
(3,188) |
5,825 |
|
- |
|
| Biondi Paul |
SVP, Head of Strategy & BD |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,619 |
7,860 |
|
- |
|
| Biondi Paul |
SVP, Head of Strategy & BD |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(647) |
3,050 |
|
- |
|
| Von Autenried Paul |
SVP, Enterp. Services & CIO |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$460,249 |
D/D |
(8,956) |
134,727 |
|
- |
|
| Von Autenried Paul |
SVP, Enterp. Services & CIO |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,925 |
141,077 |
|
- |
|
| Von Autenried Paul |
SVP, Enterp. Services & CIO |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,506) |
129,763 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-03-10 |
4 |
D |
$51.39 |
$4,415,018 |
D/D |
(85,912) |
365,199 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
173,419 |
422,683 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,984) |
322,272 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$122,462 |
D/D |
(2,383) |
17,573 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,387) |
19,956 |
|
- |
|
| Lynch Thomas J. Jr. |
EVP & Chief Scientific Officer |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,864 |
21,343 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$1,038,335 |
D/D |
(20,205) |
546,080 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,170 |
558,854 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2019-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,509) |
534,266 |
|
- |
|
| Judge Ann Powell |
SVP, Global Human Resources |
• – – |
2019-03-10 |
4 |
D |
$51.39 |
$666,169 |
D/D |
(12,963) |
73,372 |
|
- |
|
| Judge Ann Powell |
SVP, Global Human Resources |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,577 |
81,508 |
|
- |
|
960 Records found
|
|
Page 18 of 39 |
|
|
0.60 (1.47%) 
